N2OFF Reports MitoCareX Bio Shows Preliminary Anti-Inflammatory Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 12 2026
0mins
Should l Buy NITO?
N2OFF recently announced that MitoCareX Bio has shown preliminary in vitro data demonstrating inhibition of pro-inflammatory responses in human immune cells using its proprietary discovery platform. The company said, "Using MITOLINE-derived models, MitoCareX has assembled a focused library of small-molecule candidates that is now being evaluated in a suite of proprietary in-vitro assays designed to capture mitochondrial function, inflammatory signalling, and metabolic readouts. The newly reported in vitro data show that selected candidates reduce key inflammatory markers in human immune cells, providing MitoCareX Bio with an initial line of evidence that mitochondrial carrier modulation can deliver anti-inflammatory benefit in human-relevant systems. These results support further in vivo validation and lead optimization across multiple inflammatory metabolic disease indications including diseases related to the metabolic syndrome."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NITO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NITO
About NITO
N2OFF Inc. is a clean tech company, which is engaged in providing sustainable solutions for agri- tech. The Company is focused on sustainable operations in various industries, such as agri-food tech, potent greenhouse gas emissions and solar projects, specialized in eco-crop protection that helps reduce food waste and ensure food safety while reducing the use of pesticides. Its solutions are based on a blend of food acids combined with certain types of oxidizing agent-based sanitizers and, in some cases, with fungicides at low concentrations. Its products have a synergistic effect when combined with these oxidizing agent-based sanitizers and fungicides. Its green solutions are capable of cleaning, sanitizing and controlling pathogens in fresh produce. The Company’s products include Processing Aids-SavePROTECT or PeroStar, which are an application added to fruit and vegetable wash water as a processing aid to peracetic acid to increase its efficiency against plant pathogens.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
N2OFF Rebrands to Nexentis, Focusing on Biotech Innovations
- Corporate Rebranding: On February 25, 2026, N2OFF announced its rebranding to Nexentis Technologies Inc. and a trading symbol change to NXTS, reflecting its transformation into a data-driven biotech company aimed at enhancing market competitiveness.
- Acquisition of MitoCareX: On October 20, 2025, N2OFF completed the acquisition of MitoCareX, a company focused on drug discovery for resistant cancers and inflammatory metabolic diseases, marking a strategic pivot from cleantech to biotechnology.
- Validation of MITOLINE™ Platform: MitoCareX has generated multiple rounds of in vitro data using its MITOLINE™ discovery engine, demonstrating anti-tumor activity and potential applications in inflammatory metabolic diseases, indicating a promising market outlook.
- Advancing Precision Oncology Pipeline: Nexentis is progressing a pipeline targeting hard-to-treat resistant cancers and metabolic-inflammatory diseases, aiming to translate its computational discoveries into development-ready assets, which is expected to drive long-term growth in the biotech sector.
See More
N2OFF Unveils MITOLINE Algorithm for Small Molecule Drug Development
- Market Potential: The inflammatory metabolic disease market is projected to exceed $120 billion by 2030, indicating strong growth potential, with N2OFF's MitoCareX Bio positioned in this rapidly expanding sector.
- Innovative Drug Development: MitoCareX Bio is utilizing the MITOLINE algorithm to develop small-molecule drugs, with preliminary in vitro data demonstrating the ability to inhibit pro-inflammatory responses in human immune cells, laying the groundwork for future clinical studies.
- Technological Breakthrough: The MITOLINE algorithm overcomes a critical bottleneck in mitochondrial drug discovery by enabling reliable 3D comparative models, facilitating rapid identification of mitochondrial carriers implicated in oncology, autoimmune, and metabolic-inflammatory diseases, thus enhancing drug screening efficiency.
- Strategic Investment Focus: N2OFF is not only focused on drug development but also invests in renewable energy assets in Europe, showcasing its diversified business model and commitment to sustainability.
See More
N2OFF Highlights New Study on SLC25A Biomarkers and Therapeutic Targets
- Research Publication: N2OFF's wholly-owned subsidiary MitoCareX Bio co-authored a study with the University of Bari and the University of Pittsburgh, highlighting SLC25A mitochondrial carriers as potential biomarkers for spaceflight-induced dysfunction, emphasizing their significance in tumor metabolic adaptation and therapy resistance.
- Data Integration Analysis: The study integrates transcriptomic data from NASA's Open Science Data Repository, examining the expression of 53 SLC25A genes under microgravity and spaceflight-related stressors, revealing differential regulation of multiple carriers that supports their potential as biomarkers of mitochondrial and metabolic dysfunction.
- Structural Case Study: The research specifically investigates the ADP/ATP carrier AAC3, using comparative modeling and structure-function analyses to illustrate how targeting carrier conformational features can rescue mitochondrial bioenergetics under stress, further advancing precision oncology research.
- Investment Strategy Alignment: N2OFF is not only focused on drug discovery but also invests in European renewable energy assets using the RTB business model, currently serving as the lead investor in four solar projects across three EU countries, demonstrating its strategic positioning in sustainable development.
See More
N2OFF Partners with Solterra to Advance German Solar Project
- Significant Project Progress: N2OFF's partnership with Solterra has achieved key milestones in reducing permitting risks for its German solar project, which is on track for approval in Q3 2026, indicating strong positioning in the European market.
- Financial Optimization: By advancing $340,000, Solterra secured more favorable profit-sharing terms, expected to create approximately $1.7 million in project value, enhancing the company's financial flexibility and profitability.
- Strategic Investment: This transaction represents a highly efficient redeployment of limited near-term capital, not only improving long-term project economics but also enhancing future exit or operating return potential, showcasing N2OFF's discipline in capital allocation.
- Optimistic Market Outlook: With systematic reductions in regulatory risks and tightening development economics, N2OFF's advancement along the RTB value curve will lay a solid foundation for the company's long-term growth in the renewable energy sector.
See More
N2OFF Partners with Solterra to Advance European Solar Projects
- Reduced Permitting Risk: Strong progress in Germany's public consultation with zero objections and formal planning submissions in Italy enhance approval visibility, ensuring smooth project advancement.
- Over $1.69 Million in Value Creation: Strategic renegotiation in Germany optimizes returns through disciplined, capital-efficient moves, significantly improving the project's financial performance.
- High-Upside Monetization Flexibility: Italian battery storage projects are primed for value realization in H2 2026, offering options for sale or build-and-operate based on partner strategy.
- Germany Project on Track: The flagship project is on track for Q3 2026 approval, with savings exceeding $1.69 million, demonstrating strong regulatory and community support to ensure the project proceeds as planned.
See More
N2OFF: MitoCareX Discovers Promising Compounds and Targets for Preclinical Candidate Selection
Company Acquisition and Strategic Direction: N2OFF, Inc. has acquired MitoCareX Bio Ltd., with CEO Dr. Alon Silberman outlining the company's focus on precision oncology and the development of novel therapies targeting aggressive cancers using their proprietary MITOLINE™ algorithm.
Innovative Drug Discovery Approach: MitoCareX is leveraging MITOLINE™ for drug discovery, aiming to create first-in-class therapeutics that disrupt cancer metabolism, particularly for lung and pancreatic cancers, which represent a significant market opportunity.
Short-Term and Long-Term Goals: The company plans to optimize hit compounds and prepare for preclinical development in 2026, while also exploring strategic collaborations to expand MITOLINE™'s applications and generate non-dilutive revenue.
Future Outlook and Mission: MitoCareX aims to establish itself as a leader in drug discovery by focusing on mitochondrial biology and precision oncology, with a mission to transform insights into value for patients and shareholders through a scalable discovery platform.
See More
N2OFF Rebrands to Nexentis, Focusing on Biotech Innovations
- Corporate Rebranding: On February 25, 2026, N2OFF announced its rebranding to Nexentis Technologies Inc. and a trading symbol change to NXTS, reflecting its transformation into a data-driven biotech company aimed at enhancing market competitiveness.
- Acquisition of MitoCareX: On October 20, 2025, N2OFF completed the acquisition of MitoCareX, a company focused on drug discovery for resistant cancers and inflammatory metabolic diseases, marking a strategic pivot from cleantech to biotechnology.
- Validation of MITOLINE™ Platform: MitoCareX has generated multiple rounds of in vitro data using its MITOLINE™ discovery engine, demonstrating anti-tumor activity and potential applications in inflammatory metabolic diseases, indicating a promising market outlook.
- Advancing Precision Oncology Pipeline: Nexentis is progressing a pipeline targeting hard-to-treat resistant cancers and metabolic-inflammatory diseases, aiming to translate its computational discoveries into development-ready assets, which is expected to drive long-term growth in the biotech sector.
See More
N2OFF Unveils MITOLINE Algorithm for Small Molecule Drug Development
- Market Potential: The inflammatory metabolic disease market is projected to exceed $120 billion by 2030, indicating strong growth potential, with N2OFF's MitoCareX Bio positioned in this rapidly expanding sector.
- Innovative Drug Development: MitoCareX Bio is utilizing the MITOLINE algorithm to develop small-molecule drugs, with preliminary in vitro data demonstrating the ability to inhibit pro-inflammatory responses in human immune cells, laying the groundwork for future clinical studies.
- Technological Breakthrough: The MITOLINE algorithm overcomes a critical bottleneck in mitochondrial drug discovery by enabling reliable 3D comparative models, facilitating rapid identification of mitochondrial carriers implicated in oncology, autoimmune, and metabolic-inflammatory diseases, thus enhancing drug screening efficiency.
- Strategic Investment Focus: N2OFF is not only focused on drug development but also invests in renewable energy assets in Europe, showcasing its diversified business model and commitment to sustainability.
See More
N2OFF Highlights New Study on SLC25A Biomarkers and Therapeutic Targets
- Research Publication: N2OFF's wholly-owned subsidiary MitoCareX Bio co-authored a study with the University of Bari and the University of Pittsburgh, highlighting SLC25A mitochondrial carriers as potential biomarkers for spaceflight-induced dysfunction, emphasizing their significance in tumor metabolic adaptation and therapy resistance.
- Data Integration Analysis: The study integrates transcriptomic data from NASA's Open Science Data Repository, examining the expression of 53 SLC25A genes under microgravity and spaceflight-related stressors, revealing differential regulation of multiple carriers that supports their potential as biomarkers of mitochondrial and metabolic dysfunction.
- Structural Case Study: The research specifically investigates the ADP/ATP carrier AAC3, using comparative modeling and structure-function analyses to illustrate how targeting carrier conformational features can rescue mitochondrial bioenergetics under stress, further advancing precision oncology research.
- Investment Strategy Alignment: N2OFF is not only focused on drug discovery but also invests in European renewable energy assets using the RTB business model, currently serving as the lead investor in four solar projects across three EU countries, demonstrating its strategic positioning in sustainable development.
See More
N2OFF Partners with Solterra to Advance German Solar Project
- Significant Project Progress: N2OFF's partnership with Solterra has achieved key milestones in reducing permitting risks for its German solar project, which is on track for approval in Q3 2026, indicating strong positioning in the European market.
- Financial Optimization: By advancing $340,000, Solterra secured more favorable profit-sharing terms, expected to create approximately $1.7 million in project value, enhancing the company's financial flexibility and profitability.
- Strategic Investment: This transaction represents a highly efficient redeployment of limited near-term capital, not only improving long-term project economics but also enhancing future exit or operating return potential, showcasing N2OFF's discipline in capital allocation.
- Optimistic Market Outlook: With systematic reductions in regulatory risks and tightening development economics, N2OFF's advancement along the RTB value curve will lay a solid foundation for the company's long-term growth in the renewable energy sector.
See More
N2OFF Partners with Solterra to Advance European Solar Projects
- Reduced Permitting Risk: Strong progress in Germany's public consultation with zero objections and formal planning submissions in Italy enhance approval visibility, ensuring smooth project advancement.
- Over $1.69 Million in Value Creation: Strategic renegotiation in Germany optimizes returns through disciplined, capital-efficient moves, significantly improving the project's financial performance.
- High-Upside Monetization Flexibility: Italian battery storage projects are primed for value realization in H2 2026, offering options for sale or build-and-operate based on partner strategy.
- Germany Project on Track: The flagship project is on track for Q3 2026 approval, with savings exceeding $1.69 million, demonstrating strong regulatory and community support to ensure the project proceeds as planned.
See More
N2OFF: MitoCareX Discovers Promising Compounds and Targets for Preclinical Candidate Selection
Company Acquisition and Strategic Direction: N2OFF, Inc. has acquired MitoCareX Bio Ltd., with CEO Dr. Alon Silberman outlining the company's focus on precision oncology and the development of novel therapies targeting aggressive cancers using their proprietary MITOLINE™ algorithm.
Innovative Drug Discovery Approach: MitoCareX is leveraging MITOLINE™ for drug discovery, aiming to create first-in-class therapeutics that disrupt cancer metabolism, particularly for lung and pancreatic cancers, which represent a significant market opportunity.
Short-Term and Long-Term Goals: The company plans to optimize hit compounds and prepare for preclinical development in 2026, while also exploring strategic collaborations to expand MITOLINE™'s applications and generate non-dilutive revenue.
Future Outlook and Mission: MitoCareX aims to establish itself as a leader in drug discovery by focusing on mitochondrial biology and precision oncology, with a mission to transform insights into value for patients and shareholders through a scalable discovery platform.
See More
